Introduction
Variegate porphyria (VP) is the clinical syndrome resulting from deficient activity of the enzyme protoporphyrinogen oxidase (PPO)" 2 and is inherited as an autosomal dominant trait. In the heterozygous state, the clinical manifestations include neurovisceral crises or 'acute attacks' and skin disease. The cutaneous disease presents with photosensitivity which may result in blistering, erosions, a fragile skin with chronic scarring and pigmentary changes. 3 The principal biochemical findings are of an increased excretion of protoporphyrin, coproporphyrin and pentacarboxylic porphyrin in the faeces. Increased porphyrins may also be detected in plasma and urine. However, asymptomatic carriers are believed to be common, and may or may not show abnormalities of porphyrin production. The condition is unusually prevalent in South Africa, where it is one of the most frequently encountered genetic conditions. The gene frequency amongst the white Afrikaner population of South Africa has been estimated at 0.3%.4 This is ascribed to a founder effect; affected families having been traced back to a common ancestor who married at the Cape in 1688.
It is remarkable that no South African case of homozygous variegate porphyria (HVP) has yet been described despite the frequency of this gene, whereas a handful of cases have been identified elsewhere.5-'0 We describe here two further cases; one ofwhom represents the first South African case of HVP. A comparison of our cases with those previously described has allowed us to delineate a remarkably consistent syndrome; however, we describe an additional feature, a severe sensory neuropathy, which may account for some of the mutilating features of this disease.
Case reports
Case I
A female child of Afrikaner origin with a normal 46XX karyotype, born to non-consanguineous parents, developed severe blistering of the face and hands within days of birth. A diagnosis of porphyria was confirmed in our laboratory at 9 months. Her biochemical profile, assessed by thin-layer chromatography and fluoroscanning, is. characteristic of VP (Table I ). In addition, she showed an elevated erythrocyte protoporphyrin. The child's mother demonstrated the faecal porphyrin excretion pattern of VP, whereas the father had a normal profile. Both were asymptomatic. Two younger siblings were normal. An assay of PPO activity in Epstein-Barr virus-transformed Figure 1 ). Radiographs demonstrate brachydactyly with broad, short metacarpals and phalanges, and a delayed bone age ( Figure 2 ).
She has severe skin disease, manifested by blistering, erosions, crusting, pigmentation and milia. The lesions have a wider distribution than those of heterozygous VP. In addition to typical blistering and scarring of sun-exposed areas, the skin in non-exposed areas of the arms, legs and trunk is thickened and infiltrated, and clearly abnormal. Histological abnormalities were demonstrated in biopsies taken from both sun-exposed (wrist) and unexposed (buttock) skin. Both showed features of porphyria: striking perivascular PASpositive non-fluorescent hyalin deposits were present in the papillary and upper reticular dermis of exposed skin. Similar but less marked changes were present around papillary dermal vessels of unexposed skin. In addition, exposed skin showed features of acute or chronic photodamage; basketweave hyperkeratosis, epidermal atrophy with necrotic keratinocytes, and marked dermal solar elasatosis. This was not present in unexposed skin.
She has severe myopia and a pendular nystagmus. Neurological development is delayed. Her perceptual and motor development are about one year behind the expected stage of development. Verbal skills are appropriate for age and she appears to be of normal intelligence. Since the age of 3 she has suffered infrequent complex partial seizures; an electroencephalogram was, however, normal. Over the past 2 years she has developed a gross sensory neuropathy of the hands and feet, manifesting with painless trauma to the hands. Electrophysiological studies of nerve conduction have demonstrated a reduced amplitude ofconduction in the right and left median sensory nerves in keeping with a sensory neuropathy. No motor abnormalities were demonstrable. Sural nerve conduction studies were normal, yet abnormalities were shown on histological examination of a sural nerve biopsy specimen. Light and electron microscopic examination of the teased fibre preparation revealed a paucity of small unmyelinated and myelinated fibres. Wallerian degeneration was present, but most noticeable was remarkable widening ofthe nodal gaps and loss of Schwann cell cytoplasm over the gap. These features are in keeping with early segmental demyelination.
Treatment has been unrewarding. Anticonvulsants have been withheld because of their porphyrinogenic potential. The skin disease remains severe despite avoidance of light and trials of sunblockers, oral-activated charcoal and beta carotene. developmental delay, nystagmus and clinodactyly. Skin manifestations were noted from the age of 6 months. He presented to a dermatology clinic at the age of 6 with blistering and fragility of the skin of his hands, face and ears. Examination revealed hypertrichosis, hyperpigmentation, scarring and milia of these areas (Figures 3 and 4) . His biochemical profile (Table I) A review of the eight reported cases shows them, with one exception, to be remarkably similar (Table II) . Both sexes are affected and the condition presents with photosensitivity within days to months of birth. Many have been mentally retarded. Delayed development is common and most will suffer seizures. Nystagmus may be noted. Structural abnormalities of the hands are frequently reported, ranging from clinodactyly to severe deformity. Growth retardation and a retarded bone age are frequent and perhaps invariable.
Reported activities of protoporphyrinogen oxidase range from 0 to 20%. It is of interest that, with the exception discussed below, none is reported to group.bmj.com on June 1, 2017 -Published by http://pmj.bmj.com/ Downloaded from precursor concentrations nor acute attacks, despite the frequency of this complication in heterozygotes who have a much greater PPO activity.
One case, described by Coakley,'" is so exceptional that it would appear to constitute, at the very least, a different form of the condition. This child first showed signs of disease at the age of 12 (10 years later than any of the other cases), had no photosensivity, did suffer severe acute attacks and is the only case reported to have died. The biochemical findings are also exceptional; a normal stool protoporphyrin was accompanied by a markedly raised coproporphyrin. In our experience, this is incompatible with VP. Despite the reported deficiency in PPO activity in the proband and parents, therefore, we are not sure that this diagnosis was correct.
To this syndrome we now add two new observations. Clinically manifest involvement of non-sunexposed skin has not yet been reported in VP, though abnormalities on electron microscopy may be shown. It suggests that severe infiltration of the skin, presumably by porphyrins, may be sufficient to evoke cutaneous damage without the mediation of sunlight. Indeed, there is some experimental evidence that porphyrin alone, in the absence of light, may be able to induce the production of collagen by human fibroblasts." Secondly, a sensory neuropathy of this severity and in the absence of any motor involvement, is unprecedented. In our experience of 300 cases of VP,3 neuropathy was limited to those who had suffered obvious acute porphyric attacks and was predominantly a motor neuropathy. We suggest that the severe hand deformities in our first case may be at least in part neuropathic, and similar to the mutilating joint changes seen in congenital sensory neuropathies. This syndrome raises several questions which are not answerable on the basis of our current understanding of porphyria. We cannot explain how patients with HVP maintain porphyrin concentrations similar to those ofthe heterozygote in the face of the near-absence of PPO activity. The pathogenesis of this gross sensory neuropathy in the absence ofelevated porphyrin precursors is also unexplained. There is much that remains to be learned about the factors influencing the clinical expression of these diseases. With a gene frequency among the Afrikaner community estimated at three per thousand,4 homozygous cases should occur with a frequency of 2.25 per million. Thus at least seven cases would be expected in this well-defined population, yet this is the only case encountered. Further studies, designed to address these questions, are likely to enhance our understanding of the expression and the biochemical and clinical features of the more commonly encountered forms of porphyria.
